文献速递胸部肿瘤

非小细胞肺癌新辅助化疗联合免疫治疗:系统综述与荟萃分析

Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Oncol · 2024-01-01

该系统综述与荟萃分析纳入43项试验共5431例患者(其中8项随机临床试验3387例),比较新辅助化疗联合免疫治疗与新辅助化疗的疗效与安全性。结果显示,联合治疗在总生存期(HR 0.65,95%CI 0.54-0.79)、无事件生存期(HR 0.59,95%CI 0.52-0.67)、主要病理缓解(RR 3.42,95%CI 2.83-4.15)和完全病理缓解(RR 5.52,95%CI 4.25-7.15)方面均优于化疗;对于基线肿瘤PD-L1水平低于1%的患者,联合治疗的无事件生存期也显著获益(HR 0.74,95%CI 0.62-0.89)。

要点

  • 在随机临床试验中,新辅助化疗联合免疫治疗较新辅助化疗显著改善总生存期(HR 0.65,95%CI 0.54-0.79)。
  • 联合治疗组的主要病理缓解(RR 3.42)和完全病理缓解(RR 5.52)均显著优于化疗组。
  • 基线PD-L1低于1%的患者仍可从联合治疗中获得无事件生存期获益(HR 0.74)。

核心结论

  • 新辅助化疗联合免疫治疗在手术、病理和疗效结局方面均优于新辅助化疗。
  • 对于可切除的非小细胞肺癌且肿瘤PD-L1水平低于1%的患者,新辅助化疗联合免疫治疗可能带来无事件生存期获益。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和Embase自2013年1月1日至2023年10月25日的临床 trials。
  • 纳入43项符合条件试验共5431例患者(男性4020例[74.0%];中位年龄范围55-70岁),其中8项随机临床试验3387例。
  • 排除报告使用新辅助放疗(包括放化疗)、分子靶向治疗或免疫单药的观察性研究和试验。

主要发现

  • 随机临床试验中,新辅助化疗联合免疫治疗较新辅助化疗显著改善总生存期(HR 0.65;95%CI 0.54-0.79;I²=0%)。
  • 无事件生存期(HR 0.59;95%CI 0.52-0.67;I²=14.9%)亦显著优于新辅助化疗。
  • 主要病理缓解(RR 3.42;95%CI 2.83-4.15;I²=31.2%)和完全病理缓解(RR 5.52;95%CI 4.25-7.15;I²=27.4%)均优于新辅助化疗。
  • 基线肿瘤PD-L1水平低于1%的患者中,新辅助化疗联合免疫治疗较化疗显著改善无事件生存期(HR 0.74;95%CI 0.62-0.89;I²=0%)。

关键数值与推荐

  • 随机临床试验中总生存期HR 0.65(95%CI 0.54-0.79;I²=0%),无事件生存期HR 0.59(95%CI 0.52-0.67;I²=14.9%)。
  • 主要病理缓解RR 3.42(95%CI 2.83-4.15;I²=31.2%),完全病理缓解RR 5.52(95%CI 4.25-7.15;I²=27.4%)。
  • 基线PD-L1低于1%者无事件生存期HR 0.74(95%CI 0.62-0.89;I²=0%)。

临床怎么用

  • 作者认为,对于可切除的非小细胞肺癌且肿瘤PD-L1水平低于1%的患者,新辅助化疗联合免疫治疗可能带来无事件生存期获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To date, no meta-analyses have comprehensively assessed the association of neoadjuvant chemoimmunotherapy with clinical outcomes in non-small cell lung cancer (NSCLC) in randomized and nonrandomized settings. In addition, there exists controversy concerning the efficacy of neoadjuvant chemoimmunotherapy for patients with NSCLC with programmed cell death 1 ligand 1 (PD-L1) levels less than 1%. OBJECTIVE: To compare neoadjuvant chemoimmunotherapy with chemotherapy by adverse events and surgical, pathological, and efficacy outcomes using recently published randomized clinical trials and nonrandomized trials. DATA SOURCES: MEDLINE and Embase were systematically searched from January 1, 2013, to October 25, 2023, for all clinical trials of neoadjuvant chemoimmunotherapy and chemotherapy that included at least 10 patients. STUDY SELECTION: Observational studies and trials reporting the use of neoadjuvant radiotherapy, including chemoradiotherapy, molecular targeted therapy, or immunotherapy monotherapy, were excluded. MAIN OUTCOMES AND MEASURES: Surgical, pathological, and efficacy end points and adverse events were pooled using a random-effects meta-analysis. RESULTS: Among 43 eligible trials comprising 5431 patients (4020 males [74.0%]; median age range, 55-70 years), there were 8 randomized clinical trials with 3387 patients. For randomized clinical trials, pooled overall survival (hazard ratio, 0.65; 95% CI, 0.54-0.79; I2 = 0%), event-free survival (hazard ratio, 0.59; 95% CI, 0.52-0.67; I2 = 14.9%), major pathological response (risk ratio, 3.42; 95% CI, 2.83-4.15; I2 = 31.2%), and complete pathological response (risk ratio, 5.52; 95% CI, 4.25-7.15; I2 = 27.4%) favored neoadjuvant chemoimmunotherapy over neoadjuvant chemotherapy. For patients with baseline tumor PD-L1 levels less than 1%, there was a significant benefit in event-free survival for neoadjuvant chemoimmunotherapy compared with chemotherapy (hazard ratio, 0.74; 95% CI, 0.62-0.89; I2 = 0%). CONCLUSION AND RELEVANCE: This study found that neoadjuvant chemoimmunotherapy was superior to neoadjuvant chemotherapy across surgical, pathological, and efficacy outcomes. These findings suggest that patients with resectable NSCLC with tumor PD-L1 levels less than 1% may have an event-free survival benefit with neoadjuvant chemoimmunotherapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sorin M, Prosty C, Ghaleb L, et al. Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024. PMID: 38512301. doi:10.1001/jamaoncol.2024.0057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。